A
Axel Ullrich
Researcher at Max Planck Society
Publications - 436
Citations - 63142
Axel Ullrich is an academic researcher from Max Planck Society. The author has contributed to research in topics: Receptor tyrosine kinase & Tyrosine kinase. The author has an hindex of 124, co-authored 436 publications receiving 61445 citations. Previous affiliations of Axel Ullrich include Institute of Molecular and Cell Biology & Agency for Science, Technology and Research.
Papers
More filters
Journal ArticleDOI
Localization of the human insulin gene to the distal end of the short arm of chromosome 11
TL;DR: The results demonstrate chromosomal localization of the human insulin gene to 11p15 and a significant percentage of hybridized cells exhibited silver grains on the distal end of the short arm (band p15) of chromosome 11.
Journal ArticleDOI
Axl and growth arrest - Specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme
Markus Hutterer,Pjotr Knyazev,Ariane Abate,Markus Reschke,Hans Maier,Nadia Stefanova,Tatjana Knyazeva,Verena Barbieri,Markus Reindl,Armin Muigg,Herwig Kostron,Guenther Stockhammer,Axel Ullrich +12 more
TL;DR: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients, indicating that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for gli cancer treatment.
Journal ArticleDOI
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival
Peter Vajkoczy,Pjotr Knyazev,Andrea Kunkel,Hans Holger Capelle,Sandra Behrndt,Hendrik von Tengg-Kobligk,Fabian Kiessling,Uta Eichelsbacher,Marco Essig,Tracy Ann Read,Ralf Erber,Axel Ullrich,Axel Ullrich +12 more
TL;DR: The findings implicate Axl in gliomagenesis and validate it as a promising target for the development of approaches toward a therapy of these highly aggressive but, as yet, therapy-refractory, tumors.
Journal ArticleDOI
Receptor tyrosine kinases as targets for anticancer drugs.
TL;DR: In this paper, the mechanism of uncontrolled RTK signaling that leads to cancer has provided the rationale for anti-RTK drug development and strategies towards the prevention and interception of RTK signalling include monoclonal antibodies, small-molecule inhibitors, immunotoxins and antisense oligonucleotides.
Journal Article
Distinct structural characteristics of discoidin I subfamily receptor tyrosine kinases and complementary expression in human cancer.
TL;DR: CCK-2 and MCK-10 expression was found in connective and epithelial tissues, which in cancers of epithelial origin results in mutually exclusive expression in stroma and tumor cells, indicating a possible involvement of this class of RTKs in tumor invasion.